Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Betul Oran

Showing results (61-70 of 141) with videos related to

Pageof 15
Sort By:
Cancer|May 18, 2017
Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myelomaLauren W Veltri, Denái R Milton, Ruby Delgado, et al.
Leukemia & Lymphoma|July 9, 2019
Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged ≥75 yearsQaiser Bashir, Kamal Chamoun, Denái R Milton, et al.
Transplantation and Cellular Therapy|March 30, 2021
Vedolizumab for Steroid Refractory Lower Gastrointestinal Tract Graft-Versus-Host DiseaseRohtesh S Mehta, Rima M Saliba, Anna Jan, et al.
Transplantation and Cellular Therapy|May 23, 2021
Outcomes of Second Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Myeloid LeukemiaFevzi F Yalniz, Rima M Saliba, Uri Greenbaum, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 4, 2019
Allogeneic Transplantation after Myeloablative Rituximab/BEAM ± Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-Up ResultsKamal Chamoun, Denái R Milton, Celina Ledesma, et al.
Bone Marrow Transplantation|September 28, 2018
Impact of a novel prognostic model, hematopoietic cell transplant-composite risk (HCT-CR), on allogeneic transplant outcomes in patients with acute myeloid leukemia and myelodysplastic syndromePiyanuch Kongtim, Simrit Parmar, Denái R Milton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 25, 2018
Updated Results of Rituximab Pre- and Post-BEAM with or without <sup>90</sup>Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell LymphomaJad Chahoud, Dawen Sui, William D Erwin, et al.
Blood Advances|January 24, 2024
Incidence and risk factors of early onset VOD/SOS differ in younger vs older adults after stem cell transplantationCurtis Marcoux, Rima M Saliba, Whitney Wallis, et al.
Transplantation and Cellular Therapy|July 28, 2022
Post-Transplantation Cyclophosphamide Versus Tacrolimus and Methotrexate Graft-Versus-Host Disease Prophylaxis for HLA-Matched Donor TransplantationRohtesh S Mehta, Rima M Saliba, Gabriela Rondon, et al.
Leukemia & Lymphoma|October 17, 2015
Double umbilical cord blood transplant is effective therapy for relapsed or refractory Hodgkin lymphomaPhilip A Thompson, Travis Perera, David Marin, et al.
Pageof 15

Showing results (61-70 of 141) with videos related to

Sort By:
Pageof 15
Cancer|May 18, 2017
Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myelomaLauren W Veltri, Denái R Milton, Ruby Delgado, et al.
Leukemia & Lymphoma|July 9, 2019
Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged ≥75 yearsQaiser Bashir, Kamal Chamoun, Denái R Milton, et al.
Transplantation and Cellular Therapy|March 30, 2021
Vedolizumab for Steroid Refractory Lower Gastrointestinal Tract Graft-Versus-Host DiseaseRohtesh S Mehta, Rima M Saliba, Anna Jan, et al.
Transplantation and Cellular Therapy|May 23, 2021
Outcomes of Second Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Myeloid LeukemiaFevzi F Yalniz, Rima M Saliba, Uri Greenbaum, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 4, 2019
Allogeneic Transplantation after Myeloablative Rituximab/BEAM ± Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-Up ResultsKamal Chamoun, Denái R Milton, Celina Ledesma, et al.
Bone Marrow Transplantation|September 28, 2018
Impact of a novel prognostic model, hematopoietic cell transplant-composite risk (HCT-CR), on allogeneic transplant outcomes in patients with acute myeloid leukemia and myelodysplastic syndromePiyanuch Kongtim, Simrit Parmar, Denái R Milton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 25, 2018
Updated Results of Rituximab Pre- and Post-BEAM with or without <sup>90</sup>Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell LymphomaJad Chahoud, Dawen Sui, William D Erwin, et al.
Blood Advances|January 24, 2024
Incidence and risk factors of early onset VOD/SOS differ in younger vs older adults after stem cell transplantationCurtis Marcoux, Rima M Saliba, Whitney Wallis, et al.
Transplantation and Cellular Therapy|July 28, 2022
Post-Transplantation Cyclophosphamide Versus Tacrolimus and Methotrexate Graft-Versus-Host Disease Prophylaxis for HLA-Matched Donor TransplantationRohtesh S Mehta, Rima M Saliba, Gabriela Rondon, et al.
Leukemia & Lymphoma|October 17, 2015
Double umbilical cord blood transplant is effective therapy for relapsed or refractory Hodgkin lymphomaPhilip A Thompson, Travis Perera, David Marin, et al.
Pageof 15